Policy
The $1.2 trillion budget package will now move to the Senate, which is expected to hold a vote next week.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former US Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
MyoKardia, Inc. announced updates related to its hypertrophic cardiomyopathy treatment portfolio, including lead therapeutic candidate, mavacamten.
Adocia, the clinical-stage biopharmaceutical company focused on the treatment of diabetes and other metabolic diseases with innovative formulations of proteins and peptides, announces its financial results for the first six months ended June 30, 2019.
Atriva Therapeutics GmbH announced that they have received the Biomarker Validation Award as part of the European Interreg Project Codex4SME.
Eisai has received a New Drug Approval for its in-house developed anticancer agent Halaven for use in the treatment of patients with locally advanced or metastatic breast cancer, previously treated with at least two prior chemotherapy regimens, including an anthracycline and a taxane, from the China National Medical Products Administration.
A federal judge ordered that information on sales of opioids up to the year 2013 could be released.
As the 2020 election heats up, candidates for president are unveiling their plans to lower prescription drug prices.
In November 2018, Chinese researcher He Jiankui announced he had used CRISPR gene editing to modify the CCR5 genes in the embryos of seven Chinese couples. This was met by widespread condemnation, investigations and a call for a global moratorium against that type of research.
MIT’s Research Enterprise in Singapore, SMART, launches a new research group, Critical Analytics for Manufacturing Personalized-Medicine (CAMP), as part of Singapore’s National Cell Manufacturing Initiative to overcome scientific and technical challenges in life-changing cell therapies.
Phase 1/2 trial to be HOOKIPA’s first clinical trial in immuno-oncology
Although the American public, Congress and the Trump administration have pressed for meaningful legislation over drug pricing, time is running out this year.